Refine your search
Co-Authors
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All
Chand, Subhash
- Assessment of Soil Conservation Efficiencies of Selected Medicinal and Aromatic Plants in Nilgiris
Abstract Views :271 |
PDF Views:0
Authors
Source
Indian Forester, Vol 130, No 12 (2004), Pagination: 1444-1450Abstract
A study was conducted to quantify runoff and soil loss under the cultivation of prominent medicinal and aromatic plants in the high hills of Nilgiris, in order to assess their relative soil and water conservation efficiencies. Six species, namely Geranium (Pelargonium graveolens), Rosemary (Rosmarinus officinalis) , Cineraria (Ceneraria maritima), Thyme (Thymus vulgaris), Mentha (Mentha piperita) and Digitalis (Digitalis purpurea) were planted in 15 m × 5 m plots on 15 percent land slope. Geranium recorded highest average green biomass yield followed by Digitalis, Cineraria, Mentha and Rosemary. Runoff and soil loss was maximum under Thyme followed by Cineraria because of their poor canopy cover. The lowest average annual soil loss and run off, over four years, was observed from Digitalis followed by Mentha and Geranium due to their quick establishment and higher canopy coverage. Relative Soil and Water Conservation Efficiency (RSWCE) varied from 36.4 per cent under Cineraria to 96.6 percent under Digitalis with Mentha, Geranium and Rosemary registering RSWCE of 95.1, 88.4 and 87.8 percent, respectively. It is suggested that Digitalis, Mentha, Geranium and Rosemary cultivation could be the best options for a diversified land use system as well as for cover crop, intercrop and vegetative barrier in the Nilgiris for effective soil conservation.
- Preparation and Characterization of Sol Gel Derived ZnO Thin Film
Abstract Views :163 |
PDF Views:0
Authors
Affiliations
1 Department of Physics, National Institute of Technology, Hamirpur, IN
1 Department of Physics, National Institute of Technology, Hamirpur, IN
Source
Invertis Journals of Science & Technology, Vol 8, No 1 (2015), Pagination: 32-35Abstract
The structural and optical properties of ZnO thin film prepared by sol gel process using spin coating technique on glass substrate was investigated. Spin coated ZnO film was dried at 300°C and then annealed at 600°C. The XRD analysis revealed single-phase ZnO with hexagonal zincite structure. The absorption edge revealed that the optical band gap energy for the film was between 3.26-3.27eV and electronic transition was direct transition type.Keywords
ZnO Thin Film, Sol Gel, Optical Properties.Full Text
- Quality Assurance of Rituximab (Anti-CD 20) Antibodies by Potency Testing:Determining the System Suitability Criteria and Sample Acceptance Criteria
Abstract Views :255 |
PDF Views:81
Authors
Affiliations
1 National Institute of Biologicals (Ministry of Health and Family Welfare), Government of India, Plot No. A-32, Sector-62, Institutional Area, Noida 201 309, IN
1 National Institute of Biologicals (Ministry of Health and Family Welfare), Government of India, Plot No. A-32, Sector-62, Institutional Area, Noida 201 309, IN
Source
Current Science, Vol 114, No 12 (2018), Pagination: 2513-2518Abstract
A validated and robust bioassay is of paramount importance in the various stages of biosimilar development to ensure efficacy, quality and potency. The complement-dependent cytotoxicity assay was validated over six simulated potencies and found specific for rituximab-like antibodies. The bioassay was found robust with linearity parameter R2 = 0.99, %GCV for precision and accuracy was less than 20% for >40 individual performances. Detailed set of system suitability and sample acceptance criteria was determined. The study may play a key part in the development of written and physical potency reference standards for incorporation in different pharmacopeia for effective biosimilar development and regulation.Keywords
Complement-Dependent Cytotoxicity, Geometric Coefficient of Variation, Quality Assurance, Rituximab.Full Text
References
- Li, E., Subramanian, J., Anderson, S., Thomas, D., McKinley, J. and Jacobs, I. A., Development of biosimilars in an era of oncologic drug shortages. Drug Des. Dev. Ther., 2015, 9, 3247–3255.
- Cronstein, B. N., The benefits and drawbacks of biosimilars. Clin. Adv. Hematol. Oncol., 2015, 13(10), 639–641.
- Jacobs, I., Ewesuedo, R., Lula, S. and Zacharchuk, C., Biosimilars for the treatment of cancer: a systematic review of published evidence. Biodrugs, 2017, 31(1), 1–36.
- Misra, M., Biosimilars: current perspectives and future implications. Indian J. Pharmacol., 2014, 44(1), 12–14.
- USFDA, FDA guidance: guidance for industry, bioanalytical method validation. US Food and Drug Administration, 2013
- Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues, European Medicines Agency, 2014.
- CDSCO, Guidelines on similar biologics: regulatory requirements for marketing authorization in India, Central Drugs Standard Control Organization, New Delhi, 2016.
- Gurcan, H. M., Keskin, D.B., Stern, J. N., Nitzberg, M. A., Shekhani, H. and Ahmed, A. R., A review of the current use of rituximab in autoimmune diseases. Int. Immunopharmacol., 2009, 9(1), 10–25.
- Smith, M. R., Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene, 2003, 22, 7359–7368.
- Clatworthy, M. R., Targeting B cells and antibody in transplantation. Am. J. Transplant., 2011, 11(7), 1359–1367.
- Weiner, G. J., Rituximab: mechanism of action. Semin. Hematol., 2010, 47(2), 115–123.
- Boross, P. and Leusen, J. H. W., Mechanisms of action of CD20 antibodies. Am. J. Cancer. Res., 2012, 2(6), 676–690.
- Harjunpaa, A., Junnikkala, S. and Meri, S., Rituximab (anti-CD20) therapy of B-cell lymphomas: direct complement killing is superior to cellular effector mechanisms. Scand. J. Immunol., 2000, 51, 634–641.
- USP/MC; Rituximab Summary Validation Report, Report, USP Medicines Compendium, 2013.
- Reed, G. F., Lynn, F. and Meade, B. D., Use of coefficient of variation in assessing variability of quantitative assays. Clin. Diagn. Lab. Immunol., 2002, 9(6), 1235–1239.
- Biological Assay Validation. United States Pharmacopoeia, 35–NF 30, 2012.
- Dafale, N., Semwal, U., Agarwal, P., Sharma, P. and Singh, G., Development and validation of microbial bioassay for quantification of levofloxacin in pharmaceutical preparations. J. Pharm. Anal., 2015, 5(1), 18–26.
- Coffey, T, Grevenkamp, M., Wilson, A. and Hu, M., Biological assay qualification using design of experiments. Bioprocess. Int., 2013, 11(6), 42–49.
- Tsiftsoglou, A. S., Ruiz. S. and Schneider, C. K., Development and regulation of biosimilars: current status and future challenges. BioDrugs., 2013, 27(3), 203–211.
- ICH harmonised tripartite guideline, ‘Validation on analytical procedures: text and (methodology)’, International Council for Harmonisation, Q2 (R1), Step 4, 2005.
- Design and development of biological assays, United States Pharmacopoeia, 35–NF 30, 2012.